Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Journey Medical (DERM) Non Operating Income: 2020-2025

Historic Non Operating Income for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to -$786,000.

  • Journey Medical's Non Operating Income fell 255.95% to -$786,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 million, marking a year-over-year decrease of 1462.56%. This contributed to the annual value of -$934,000 for FY2024, which is 40.09% up from last year.
  • Journey Medical's Non Operating Income amounted to -$786,000 in Q3 2025, which was up 8.60% from -$860,000 recorded in Q2 2025.
  • Journey Medical's 5-year Non Operating Income high stood at $504,000 for Q3 2024, and its period low was -$4.4 million during Q4 2021.
  • Over the past 3 years, Journey Medical's median Non Operating Income value was -$575,000 (recorded in 2023), while the average stood at -$444,364.
  • As far as peak fluctuations go, Journey Medical's Non Operating Income slumped by 2,016.02% in 2021, and later soared by 239.61% in 2024.
  • Quarterly analysis of 5 years shows Journey Medical's Non Operating Income stood at -$4.4 million in 2021, then skyrocketed by 85.46% to -$634,000 in 2022, then spiked by 113.72% to $87,000 in 2023, then slumped by 849.43% to -$652,000 in 2024, then crashed by 255.95% to -$786,000 in 2025.
  • Its Non Operating Income was -$786,000 in Q3 2025, compared to -$860,000 in Q2 2025 and -$749,000 in Q1 2025.